Janus Henderson Group PLC Boosts Stock Position in Edwards Lifesciences Corporation $EW

Janus Henderson Group PLC increased its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 1.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,165,604 shares of the medical research company’s stock after purchasing an additional 18,985 shares during the period. Janus Henderson Group PLC’s holdings in Edwards Lifesciences were worth $93,334,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of EW. Evermay Wealth Management LLC lifted its position in Edwards Lifesciences by 4.0% during the fourth quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock valued at $282,000 after purchasing an additional 128 shares during the last quarter. Rehmann Capital Advisory Group grew its stake in shares of Edwards Lifesciences by 2.1% in the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after buying an additional 130 shares in the last quarter. Florida Trust Wealth Management Co increased its holdings in shares of Edwards Lifesciences by 1.5% in the 4th quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company’s stock worth $751,000 after buying an additional 132 shares during the last quarter. McIlrath & Eck LLC increased its holdings in shares of Edwards Lifesciences by 14.6% in the 4th quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock worth $90,000 after buying an additional 135 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its position in shares of Edwards Lifesciences by 0.9% during the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock valued at $1,288,000 after buying an additional 136 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction on Friday, July 10th. The stock was sold at an average price of $91.70, for a total transaction of $56,762.30. Following the transaction, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,671,117.80. This represents a 1.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 44,558 shares of company stock worth $3,770,939. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $86.17 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The stock has a market cap of $49.62 billion, a price-to-earnings ratio of 49.52, a price-to-earnings-growth ratio of 2.18 and a beta of 0.86. The firm has a 50-day moving average of $87.91 and a two-hundred day moving average of $83.89. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. The company’s revenue was up 13.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analysts Set New Price Targets

EW has been the subject of a number of analyst reports. Citigroup increased their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. JPMorgan Chase & Co. boosted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Friday, July 24th. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. UBS Group initiated coverage on Edwards Lifesciences in a research note on Tuesday. They issued a “buy” rating and a $110.00 price objective for the company. Finally, Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.